Skip to main navigation Skip to search Skip to main content

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. German Society of Rheumatology, (DGRh) 2017, Stuttgart, Germany, September 2017.

Research output: Contribution to conference › Poster

Original languageAmerican English
StatePublished - Sep 2017
EventGerman Society of Rheumatology, (DGRh) -
Duration: Sep 1 2017 → …

Conference

ConferenceGerman Society of Rheumatology, (DGRh)
Period09/1/17 → …

Disciplines

  • Rheumatology

Cite this